Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Documents de recerca, 1 registres trobats
Articles 2 registres trobats  
1.
13 p, 1.8 MB The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment / Ariceta Iraola, Gema (Hospital Universitari Vall d'Hebron) ; Dixon, B.P. (Renal Section. Department of Pediatrics. University of Colorado School of Medicine) ; Kim, S.H. (Department of Pediatrics. Pusan National University Children's Hospital) ; Kapur, G. (Faculty of Pediatric Sciences. Central Michigan University. Mount Pleasant) ; Mauch, T. (Department of Nephrology and Hypertension. Division of Pediatrics. University of Utah) ; Ortiz, S. (Clinical and Non-Clinical Pharmacology. Alexion Pharmaceuticals Inc.) ; Vallee, M. (Biostatistics. Alexion Pharmaceuticals Inc.) ; Denker, A.E. (Clinical Development. Alexion Pharmaceuticals Inc.) ; Kang, H.G. (Division of Pediatric Nephrology. Department of Pediatrics. Seoul National University College of Medicine) ; Greenbaum, L.A. (Division of Pediatric Nephrology. Emory University School of Medicine and Children's Healthcare of Atlanta) ; Lovell, H. ; Muff-Luett, M. ; Malone, K. ; Adeagbo, O. ; Wilkerson, A. ; Fraga Rodríguez, Gloria María (Institut d'Investigació Biomèdica Sant Pau) ; Sarri, S. ; Cheong, H.I. ; Ahn, Y.H. ; Han, K.H.
Ravulizumab, a long-acting complement C5 inhibitor engineered from eculizumab, allows extending maintenance dosing from every 2-3 weeks to every 4-8 weeks depending on bodyweight. Here, we evaluated the efficacy and safety of ravulizumab in complement inhibitor-naïve children (under 18 years) with atypical hemolytic uremic syndrome. [...]
2021 - 10.1016/j.kint.2020.10.046
Kidney International, Vol. 100 Núm. 1 (july 2021) , p. 225-237  
2.
12 p, 926.4 KB Combined study of 13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing / Fidalgo, Teresa (Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal)) ; Martinho, Patrícia (Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal)) ; Pinto, Catarina S. (Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal)) ; Oliveira, Ana C. (Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal)) ; Salvado, Ramon (Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal)) ; Borràs, Nina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Coucelo, Margarida (Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal)) ; Manco, Licínio (University of Coimbra) ; Maia, Tabita (Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal)) ; Mendes, M. João (Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal)) ; Del Orbe Barreto, Rafael Andrés (Instituto de Investigación Sanitaria Biocruces Bizkaia) ; Corrales Insa, Irene (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Vidal, Francisco (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ribeiro, M. Letícia (Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal)) ; Universitat Autònoma de Barcelona
The 2 main forms of thrombotic microangiopathy () are thrombotic thrombocytopenic purpura () and atypical hemolytic uremic syndrome (). Deficiency of 13 and dysregulation of the complement pathway result in and , respectively; however, overlap of their clinical characteristics makes differential diagnosis challenging. [...]
2017 - 10.1002/rth2.12016
Research and Practice in Thrombosis and Haemostasis, Vol. 1 (june 2017) , p. 69-80  

Documents de recerca 1 registres trobats  
1.
1 p, 568.8 KB An overview of the 2011 outbreak in Germany : the role of E.coli O104:H4 / Navarro, Yolanda-Maria ; Luquín Fernández, M., (Marina), dir. (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Universitat Autònoma de Barcelona. Facultat de Biociències
2013
Grau en Biologia [812]  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.